Michael W Bonney - Net Worth and Insider Trading
Michael W Bonney Net Worth
The estimated net worth of Michael W Bonney is at least $7 Million dollars as of 2024-09-20. Michael W Bonney is the Director of Alnylam Pharmaceuticals Inc and owns about 20,029 shares of Alnylam Pharmaceuticals Inc (ALNY) stock worth over $5 Million. Michael W Bonney is the Director of Sarepta Therapeutics Inc and owns about 7,051 shares of Sarepta Therapeutics Inc (SRPT) stock worth over $885,535. Michael W Bonney is also the Director of Bristol-Myers Squibb Co and owns about 9,189 shares of Bristol-Myers Squibb Co (BMY) stock worth over $453,064. Besides these, Michael W Bonney also holds Celgene Corp (CELG) , Tekla World Healthcare Fund (THW) , Kaleido Biosciences Inc (KLDO) . Details can be seen in Michael W Bonney's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Michael W Bonney has not made any transactions after 2023-12-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Michael W Bonney
Michael W Bonney Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Michael W Bonney owns 11 companies in total, including Bristol-Myers Squibb Co (BMY) , Alnylam Pharmaceuticals Inc (ALNY) , and Kaleido Biosciences Inc (KLDO) among others .
Click here to see the complete history of Michael W Bonney’s form 4 insider trades.
Insider Ownership Summary of Michael W Bonney
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
BMY | Bristol-Myers Squibb Co | 2019-12-04 | director |
ALNY | Alnylam Pharmaceuticals Inc | 2023-12-27 | director |
KLDO | Kaleido Biosciences Inc | 2019-02-28 | director & Executive Chair |
2018-06-20 | director | ||
2019-09-09 | director | ||
2018-06-14 | director | ||
2016-02-08 | director | ||
2015-08-17 | director | ||
2014-07-28 | director | ||
2011-12-13 | director | ||
2011-12-13 | director |
Michael W Bonney Latest Holdings Summary
Michael W Bonney currently owns a total of 6 stocks. Among these stocks, Michael W Bonney owns 20,029 shares of Alnylam Pharmaceuticals Inc (ALNY) as of December 27, 2023, with a value of $5 Million and a weighting of 76.25%. Michael W Bonney owns 7,051 shares of Sarepta Therapeutics Inc (SRPT) as of September 9, 2019, with a value of $885,535 and a weighting of 12.37%. Michael W Bonney also owns 9,189 shares of Bristol-Myers Squibb Co (BMY) as of December 4, 2019, with a value of $453,064 and a weighting of 6.33%. The other 3 stocks Celgene Corp (CELG) , Tekla World Healthcare Fund (THW) , Kaleido Biosciences Inc (KLDO) have a combined weighting of 5.05% among all his current holdings.
Latest Holdings of Michael W Bonney
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
ALNY | Alnylam Pharmaceuticals Inc | 2023-12-27 | 20,029 | 272.63 | 5,460,506 |
SRPT | Sarepta Therapeutics Inc | 2019-09-09 | 7,051 | 125.59 | 885,535 |
BMY | Bristol-Myers Squibb Co | 2019-12-04 | 9,189 | 49.31 | 453,064 |
CELG | Celgene Corp | 2016-03-03 | 2,000 | 108.24 | 216,480 |
THW | Tekla World Healthcare Fund | 2015-08-17 | 10,917 | 13.31 | 145,271 |
KLDO | Kaleido Biosciences Inc | 2019-02-28 | 1,651,196 | 0.00 | 165 |
Holding Weightings of Michael W Bonney
Michael W Bonney Form 4 Trading Tracker
According to the SEC Form 4 filings, Michael W Bonney has made a total of 2 transactions in Alnylam Pharmaceuticals Inc (ALNY) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Alnylam Pharmaceuticals Inc is the sale of 30,000 shares on December 27, 2023, which brought Michael W Bonney around $6 Million.
According to the SEC Form 4 filings, Michael W Bonney has made a total of 0 transactions in Sarepta Therapeutics Inc (SRPT) over the past 5 years. The most-recent trade in Sarepta Therapeutics Inc is the acquisition of 2,000 shares on September 9, 2019, which cost Michael W Bonney around $173,480.
According to the SEC Form 4 filings, Michael W Bonney has made a total of 1 transactions in Bristol-Myers Squibb Co (BMY) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Bristol-Myers Squibb Co is the acquisition of 88 shares on December 4, 2019, which cost Michael W Bonney around $5,183.
More details on Michael W Bonney's insider transactions can be found in the Insider Trading History of Michael W Bonney table.Insider Trading History of Michael W Bonney
- 1
Michael W Bonney Trading Performance
GuruFocus tracks the stock performance after each of Michael W Bonney's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Michael W Bonney is 8.3%. GuruFocus also compares Michael W Bonney's trading performance to market benchmark return within the same time period. The performance of stocks bought by Michael W Bonney within 3 months outperforms 4 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Michael W Bonney's insider trading performs compared to the benchmark.
Performance of Michael W Bonney
Michael W Bonney Ownership Network
Michael W Bonney Owned Company Details
What does Bristol-Myers Squibb Co do?
Who are the key executives at Bristol-Myers Squibb Co?
Michael W Bonney is the director of Bristol-Myers Squibb Co. Other key executives at Bristol-Myers Squibb Co include EVP & Chief Commercial Officer Christopher S. Boerner , EVP & Corporate Affairs Cari Gallman , and SVP & Human Resources Ann Powell Judge .
Bristol-Myers Squibb Co (BMY) Insider Trades Summary
Over the past 18 months, Michael W Bonney made no insider transaction in Bristol-Myers Squibb Co (BMY). Other recent insider transactions involving Bristol-Myers Squibb Co (BMY) include a net purchase of 5,071 shares made by Christopher S. Boerner , a net sale of 50,385 shares made by Rupert Vessey , and a net sale of 17,986 shares made by Ann Powell Judge .
In summary, during the past 3 months, insiders sold 0 shares of Bristol-Myers Squibb Co (BMY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 69,103 shares of Bristol-Myers Squibb Co (BMY) were sold and 13,571 shares were bought by its insiders, resulting in a net sale of 55,532 shares.
Bristol-Myers Squibb Co (BMY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Bristol-Myers Squibb Co Insider Transactions
Michael W Bonney Mailing Address
Above is the net worth, insider trading, and ownership report for Michael W Bonney. You might contact Michael W Bonney via mailing address: 65 Hayden Ave, Lexington Ma 02421.